The proline 12 alanine substitution in the PPARgamma2 gene is associated with increased extent of coronary artery disease in men.

Objective: To determine whether there is an independent association between the Pro12Ala polymorphism in the peroxisome proliferator-activated-receptor gamma2 (PPARgamma2)-gene and the extent of coronary artery disease in men.

Research Design And Methods: We determined the Pro12Ala polymorphism in the PPARgamma2 gene in 240 male patients undergoing elective coronary angiograpy, and quantitated the degree of CAD by evaluating the extent-score which better correlates with known risk factors than other measures of CAD.

Results: The presence of the 12Ala allele was significantly associated with higher CAD extent (r=0.

Endothelial Lipase: a key player in HDL metabolism modulates inflammation and atherosclerotic risk.

Endothelial Lipase (EL) is a newly identified member of the triacylglycerol lipase family. Recent studies suggested that EL may be an important determinant of HDL-metabolism and inflammation acting at the level of the vessel wall. The aim of this review is to summarize important facts derived from experimental approaches and from epidemiologic human studies to provide a comprehensive view on the role of EL in inflammation and atherogenesis as well as target for potential pharmaceutical interventions.

Single-dose comparison of formoterol (Oxis) Turbuhaler 6 microg and formoterol Aerolizer 12 microg in moderate to severe asthma: a randomised, crossover study.

Formoterol inhaled via Turbuhaler (Oxis) or Aerolizer (Foradil) produces fast and long-lasting bronchodilation in asthmatic patients. While formoterol Turbuhaler provides sustained efficacy for > or =12h at a metered dose of 6 microg (delivered dose 4.5 microg), the recommended metered dose for formoterol Aerolizer is 12 microg (delivered dose unknown).

A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).

Paclitaxel is a new antineoplastic agent with activity in lung cancer. This phase I clinical trial was designed to determine the maximum tolerated dose (MTD) of paclitaxel in combination with etoposide in previously untreated patients with non-small cell lung cancer (NSCLC). Doses of paclitaxel were in the range of 150-225 mg/m2 (d1) and of etoposide in the range of 100-120 mg/m2 (d2-4).

[Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin].

There is evidence that neoadjuvant chemotherapy may improve treatment results in patients with locally advanced NSCLC. The aim of the present study was to increase resectability rates by induction chemotherapy in NSCLC stage IIIA/IIIB with the new cytostatic combination, paclitaxel and carboplatin. Neoadjuvant treatment consisted of 3 cycles (q21) of chemotherapy with paclitaxel (200 mg/m(2)) and carboplatin (AUC 6).

[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance].

The aim of the present study was to compare the efficacy and the tolerability of salmeterol and theophylline in patients with nocturnal asthma. 16 patients were entered into a randomized, double-blind, crossover trial. Using a double-dummy technique, salmeterol (50 micrograms b.

[Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)].

In initial studies the dose-limiting toxicity of paclitaxel monotherapy was leukopenia. In these studies, paclitaxel was administered over 24 hrs. The aim of the present phase II clinical trial was to investigate the efficacy and the hematological toxicity of a 3 hr paclitaxel infusion in previously untreated patients with NSCLC.

[Hyperfractionated irradiation of non-small cell bronchial cancer. Final results of a Phase II study].

The study was performed for the evaluation of hyperfractionated radiotherapy in the treatment of non-small-cell lung cancer. From radiobiological data we expected that the twice daily irradiation with reduced single dose should result in a better sparing of the slowly proliferating healthy lung tissue without any loss in the tumoricidal effect. 34 patients were treated conventionally with 30 daily fractions of 2.

[Thoracoscopic treatment of spontaneous pneumothorax using fibrin pleurodesis].

In 33 patients with a recurrent spontaneous pneumothorax, a thoracoscopic pleurodesis with fibrin glue was performed under local anesthesia. During an average postoperative observation period of 4 years the relapse frequency was 39% (13 cases). In these cases thoracotomy was performed and a new relapse of pneumothorax occurred in 3 patients (23%): Application of thoracoscopy with fibrin glue pleurodesis should only be applied in those patients without large emphysema vesicles and without large coalescences.

[Long-term results with the CARE classification for assessing operability before thoracic surgery].

The classification and quantification of the individual risk in accordance with the CARE scheme is suitable not only for enabling appropriate selective peri-operative and post-operative function-supporting therapy, but also for reducing long-term morbidity. The prognosis of both operated and non-operated tumour patients, is determined exclusively by the recurrence and progression of the tumour disease.

[Hyperfractionated irradiation of bronchial cancer. Results of a pilot study].

The results achieved during recent years in experimental radiotherapy of malignant tumors show more and more the benefit provided by the small individual doses applied in fractionated irradiation. The effects and side effects of a hyperfractionated therapy of the bronchial carcinoma were investigated in a not randomized comparative study. The data of 100 patients were available for evaluation; they showed a tendency to local superiority of hyperfractionated irradiation.

Lymphocytic plasmocytoid lymphoma with a three-banded gammopathy: reactivity of one of these paraproteins with cytomegalovirus.

We report the case of a 70-year-old woman suffering from small lymphocytic, plasmocytoid lymphoma with abdominal lymphomas and infiltration of the lung and the bone marrow. A three-banded, IgG lambda, IgM lambda and IgA lambda-paraproteinemia was determined using immunofixation. Because of the patient's high antibody titre against cytomegalovirus (CMV), the possible reactivity of these paraproteins with CMV was studied.

Drug-resistant bronchial asthma successfully treated with plasma exchange.

Two patients suffering from allergic bronchial asthma who showed no improvement despite six and four weeks, respectively, of drug therapy were successfully treated with therapeutic plasma exchange. The first patient had no attacks over a period of five months, and the other patient had none for over one year. Although this report only deals with single observations, we believe that therapeutic plasma exchange is of particular value for patients with severe allergic bronchial asthma because it eliminates in addition to immunocomplexes other substances, including antigens, rapidly from the blood.

Palliative therapy of tumor-induced pleural effusions with 90Yttrium-silicate.

In 20 patients with rapidly recurring malignant pleural effusion, 90Yttrium-silicate was intrapleurally instilled after the puncture. In all patients this treatment resulted in marked reduction, or even interruption, of exudate formation. Eleven patients died with an average survival of 166 days.